Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options.

作者: Francesco Sartini , Michele Figus , Marco Nardi , Giamberto Casini , Chiara Posarelli

DOI: 10.1038/S41433-019-0381-7

关键词:

摘要: Central serous chorioretinopathy is one of the most frequent causes vision reduction among middle-aged men. This disease usually has a self-limiting course, but sometimes it lasts more than 4–6 months or second episode follows complete resolution first one. Nevertheless, to date no consensus exists about duration threshold and therapy protocols for these non-resolving central chorioretinopathy. Treatment as half-dose half-fluence photodynamic therapy, subthreshold micropulse laser treatment, mineralocorticoid receptor antagonists, intravitreal anti-angiogenic drugs, transpupillary thermal anti-androgenic methotrexate, Rifampicin melatonin are described in this review. Complications very uncommon end-point results like macular thickness best-corrected visual acuity improvement difficult compare different therapeutic modalities due follow-up lack homogeneity patient recruitment. The aim review focusing on treatment chronic forms with comprehensive recent management updates according latest clinical trial results.

参考文章(102)
A Pirracchio, F Bandello, G Virgili, P Lanzetta, U Menchini, ICG angiography and retinal pigment epithelial decompensation (CRSC and epitheliopathy) Journal Francais D Ophtalmologie. ,vol. 24, pp. 448- 451 ,(2001)
E Moisseiev, A J Holmes, A Moshiri, L S Morse, Finasteride is effective for the treatment of central serous chorioretinopathy Eye. ,vol. 30, pp. 850- 856 ,(2016) , 10.1038/EYE.2016.53
Mathieu Lehmann, Elodie Bousquet, Talal Beydoun, Francine Behar-Cohen, PACHYCHOROID: an inherited condition? Retina-the Journal of Retinal and Vitreous Diseases. ,vol. 35, pp. 10- 16 ,(2015) , 10.1097/IAE.0000000000000287
George J Manayath, Venkatapathy Narendran, Saurabh Arora, Rodney J Morris, Veerappan R Saravanan, Parag K Shah, None, Graded subthreshold transpupillary thermotherapy for chronic central serous chorioretinopathy. Ophthalmic Surgery Lasers & Imaging. ,vol. 43, pp. 284- 290 ,(2012) , 10.3928/15428877-20120618-06
Shree K. Kurup, Armando Oliver, Andres Emanuelli, Vincent Hau, David Callanan, Low-dose methotrexate for the treatment of chronic central serous chorioretinopathy: a retrospective analysis. Retina-the Journal of Retinal and Vitreous Diseases. ,vol. 32, pp. 2096- 2101 ,(2012) , 10.1097/IAE.0B013E31825DD281
Min Cheol Shin, Ji Won Lim, CONCENTRATION OF CYTOKINES IN THE AQUEOUS HUMOR OF PATIENTS WITH CENTRAL SEROUS CHORIORETINOPATHY Retina-the Journal of Retinal and Vitreous Diseases. ,vol. 31, pp. 1937- 1943 ,(2011) , 10.1097/IAE.0B013E31820A6A17
Adrian T Fung, Lawrence A Yannuzzi, K Bailey Freund, None, TYPE 1 (SUB-RETINAL PIGMENT EPITHELIAL) NEOVASCULARIZATION IN CENTRAL SEROUS CHORIORETINOPATHY MASQUERADING AS NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Retina-the Journal of Retinal and Vitreous Diseases. ,vol. 32, pp. 1829- 1837 ,(2012) , 10.1097/IAE.0B013E3182680A66
Alexander Ross, Adam H Ross, Quresh Mohamed, Review and update of central serous chorioretinopathy. Current Opinion in Ophthalmology. ,vol. 22, pp. 166- 173 ,(2011) , 10.1097/ICU.0B013E3283459826
Quraish Ghadiali, Jesse J Jung, Suqin Yu, Samir N Patel, Lawrence A Yannuzzi, None, CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH MINERALOCORTICOID ANTAGONISTS: A ONE-YEAR PILOT STUDY Retina-the Journal of Retinal and Vitreous Diseases. ,vol. 36, pp. 611- 618 ,(2016) , 10.1097/IAE.0000000000000748
Alejandra Daruich, Alexandre Matet, Ali Dirani, Mathilde Gallice, Luke Nicholson, Sobha Sivaprasad, Francine Behar-Cohen, Oral Mineralocorticoid-Receptor Antagonists: Real-Life Experience in Clinical Subtypes of Nonresolving Central Serous Chorioretinopathy With Chronic Epitheliopathy. Translational Vision Science & Technology. ,vol. 5, pp. 2- 2 ,(2016) , 10.1167/TVST.5.2.2